Discounted Cash Flow
Privia Health Group, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $786.4m | $-299.0k | $24.4m | -0.0% | $0.09 |
| 2020 | $817.1m (3.9%) | $-340.0k (-13.7%) | $38.5m (58.1%) | -0.0% (-9.4%) | $0.33 (266.7%) |
| 2021 | $966.2m (18.3%) | $-2.4m (-611.5%) | $54.5m (41.5%) | -0.3% (-501.6%) | $-1.83 (-654.5%) |
| 2022 | $1.4b (40.4%) | $-3.5m (-43.8%) | $47.1m (-13.6%) | -0.3% (-2.4%) | $-0.08 (95.6%) |
| 2023 | $1.7b (22.2%) | $-2.1m (41.0%) | $80.7m (71.3%) | -0.1% (51.8%) | $0.20 (350.0%) |
| 2024 | $1.7b (4.7%) | $2.7m (229.6%) | $108.5m (34.5%) | 0.2% (223.8%) | $0.12 (-40.0%) |
| 2025 | $2.1b (22.3%) | $6.8m (156.0%) | $162.2m (49.4%) | 0.3% (109.4%) | $0.19 (58.3%) |
| 2026 | $477.4m (-77.5%) | $-37.6m (-651.8%) | $24.4m (-85.0%) | -7.9% (-2553.8%) | $-0.40 (-310.5%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.